Introduction
Hepatectomy is recommended when colorectal liver metastasis (CRLM) is conducive to curative resection, with a post-hepatectomy 5-year survival rate ranging from 35 to 58% [1] [2] [3] [4] . Even in cases of initially unresectable CRLM, conversion hepatectomy can sometimes be performed after effective downsizing by chemotherapy. Adam reported 5-and 10-year survival rates of 33% and 27%, respectively, in patients with initially unresectable disease who underwent resection after downsizing via chemotherapy [5] . Over recent years, progress in colorectal cancer treatment has created more opportunities for patients with CRLM to undergo hepatectomy, but CRLM with bile duct tumor thrombus (BDTT) is rare in clinical practice. This work has been reported in line with the SCARE criteria [6] .
Presentation of case
A 76-year-old Japanese man underwent right hemicolectomy with lymph node dissection for ascending colon cancer, which was categorized as T3N1aM0 Stage IIIB in UICC, pathologically moderately differentiated adenocarcinoma. The patient subsequently received adjuvant chemotherapy with tegafur/uracil plus leucovorin. However, this treatment was discontinued after two cycles due to interstitial pneumonia.
Eighteen months after hemicolectomy, the patient had no complaint, but computed tomography (CT) revealed a hepatic portal tumor with right biliary tract dilatation (Fig. 1a, b) . (0.6 mg/dL). Tumor markers test results were within the normal range, with CEA of 4.9 ng/mL and CA19-9 of 17.8 U/mL. Magnetic resonance imaging and magnetic resonance cholangiopancreatography revealed a ring-enhanced low-intensity area in liver segment VIII involving the biliary tract (Fig. 1c, d ). Endoscopic retrograde cholangiopancreatography showed that the hepatic portal tumor extended from the hilar bile duct to the bilateral extrahepatic bile ducts. Bile cytology did not prove carcinoma. Although preoperative diagnosis was not definitive for primary cholangiocarcinoma or metastatic cancer, hepatectomy was planned.
The patient underwent right and caudate lobectomy with resection of extrahepatic biliary tract plus hepaticojejunostomy. Macroscopic examination revealed that a 12-mm tumor had developed in liver segment VIII, invaded the adjacent biliary tract, and formed a tumor thrombus in the bile duct (Fig. 2) . Microscopic examination showed that both the liver tumor and BDTT comprised moderately differentiated tubular adenocarcinoma (Fig. 3) . These pathological findings supported a diagnosis of liver metastasis with BDTT that had originated from the previous colon cancer. The tumors had the KRAS (G12 V) mutation. We detected no malignant cells in the resected stump of the biliary tract, and no metastasis in the dissected lymph nodes along the hepatoduodenal ligament.
Postoperatively, physical examination and blood test was performed every two months. Six months after hepatectomy, the patient exhibited a high total bilirubin level of 3.1 mg/dL and CA19-9 level of 455 U/mL. A CT scan showed a recurrent tumor developing in the biliary tract on the hepaticojejunostomy and intra-hepatic bile duct dilatation (Fig. 4) . The patient was administered radiation Fig. 2 . Macroscopic examination of the resected specimen. A 12-mm tumor in liver segment VIII, which invaded to the adjacent biliary tract and progressed along the right hepatic duct to the tumor thrombus was revealed. therapy (2 Gy per fraction, 50 Gy total) to reduce the tumor size and relieve obstructive jaundice. However, the tumor progressed again, leading to the patient's death one year after the hepatectomy (two years and seven months after the primary surgery).
Discussion
Liver is the most common site of metastasis from colorectal cancer. The Japanese Society for Cancer of the Colon and Rectum report a 10.9% rate of synchronous CRLM, and a 7.1% rate of metachronous CRLM [1] . Knijn et al. analyzed nine papers describing bile duct invasion of CRLM and reported a 30.2% rate of bile duct invasion in patients with CRLM [7] [8] [9] [10] [11] [12] [13] . However, there were few reports about CRLM forming intrabiliary tumor mass. We used the term of BDTT for intrabiliary tumor mass in this report, because BDTT is often used in the field of hepatology under the similar disease state [14] .
BDTT is defined as a tumor mass that develops within a bile duct. Zeng describes a model of HCC invasion and metastasis of BDTT, in which tumor cells invade the submucosa of adjacent small bile ducts, disseminate along the biliary tract, intrude into the bile duct lumen, and finally form BDTT [14] . During the course of bile duct invasion, BDTT is considered to be of an advanced stage. Compared to HCC, BDTT is extremely rare in CRLM.
In therapeutic strategies for CRLM, a negative resection margin is considered the most important factor. Most studies report that prognostic factors include the size and number of CRLM and organ metastasis except to the liver [15] [16] [17] [18] [19] . Additionally, some evidence indicates that age, high CEA level, and pathology of poorly differentiated adenocarcinoma are also prognostic factors [15] [16] [17] [18] [19] .
Some studies have not found any correlation between CRLM bile duct invasion and clinical outcomes [7, 20] . In our present case, hepatectomy was performed for CRLM with BDTT since the prehepatectomy examination revealed no lymph node or extrahepatic organ metastases. The patient had a negative surgical margin, non-multiple CRLM, pathology of moderately differentiated adenocarcinoma and low CEA level, but he had a poor prognosis. This case indicated that CRLM with BDTT might be associated with a bad prognosis, because BDTT is categorized as an advanced stage of bile duct invasion.
Conclusion
We reported here a case of metachronous CRLM with BDTT. To date, there is no available evidence guiding therapy for CRLM with BDTT. Hepatectomy is a common therapeutic procedure for CRLM, but our experience indicates that CRLM with BDTT might be associated with a bad prognosis.
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